ABCL 8-K: SEC filing

Filed with the SEC on · accession 0001703057-26-000058

ABCL filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

AbCellera Biologics Inc. furnished an 8-K reporting its financial and operational results for the quarter ended September 30, 2026, and made available a related corporate presentation for its earnings call.

Key details

RegistrantAbCellera Biologics Inc.
Chief executive officer and directorCarl L. G. Hansen

✦ Ask GOAX AI about this filing — what it means for ABCL, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ABCL?

Click here

Frequently asked questions

What did ABCL file with the SEC on Nov 9, 2026?

ABCL filed a 8-K (SEC filing). AbCellera Biologics Inc. furnished an 8-K reporting its financial and operational results for the quarter ended September 30, 2026, and made available a related corporate presentation for its earnings call.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other ABCL SEC filings

Get alerts when ABCL files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days